22nd Jun 2015 08:58
LONDON (Alliance News) - Biofrontera AG said Monday that it has completed the final steps ahead of its new drug application to the US Food and Drug Administration for its treatment for actinic keratosis Ameluz, and its BF-RhodoLED lamp.
Ameluz uses what its called photodynamic therapy- or light therapy- and is applied to the skin which is then illuminated with a strong red light to trigger a chemical reaction.
Biofrontera has submitted a drug master file for the active substance in the treatment, and it has registered Biofrontera Pharma GmbH as the manufacturer of the BF-RhodoLED lamp.
The company said it is now preparing the final documents, and expects to make the new drug application submission shortly.
Shares in Biofrontera are untraded Monday morning, it last closed at 194.80 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L